Keros Therapeutics, Inc. financial data

Symbol
KROS on Nasdaq
Location
1050 Waltham Street, Suite 302, Lexington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.02K % +5.63%
Debt-to-equity 7.75 % -13.2%
Return On Equity 2.96 %
Return On Assets 2.74 %
Operating Margin 0.13 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40.6M shares +8.24%
Common Stock, Shares, Outstanding 40.6M shares +12.3%
Entity Public Float 1.3B USD +43.6%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 40.6M shares +12.5%
Weighted Average Number of Shares Outstanding, Diluted 40.6M shares +12.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 18.2M USD
Revenue from Contract with Customer, Excluding Assessed Tax 233M USD +85820%
Research and Development Expense 187M USD +24.4%
General and Administrative Expense 45.5M USD +18%
Operating Income (Loss) 312K USD +21.1%
Nonoperating Income (Expense) 26.6M USD +29%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -32.9M USD +27.3%
Income Tax Expense (Benefit) -2.22M USD
Net Income (Loss) Attributable to Parent 18.8M USD +32.2%
Earnings Per Share, Basic 0 USD/shares +39.2%
Earnings Per Share, Diluted 0 USD/shares +39.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 690M USD +70.1%
Accounts Receivable, after Allowance for Credit Loss, Current 15.8M USD +395300%
Other Assets, Current 2.52M USD +334%
Assets, Current 733M USD +69.4%
Property, Plant and Equipment, Net 4.84M USD +12.7%
Operating Lease, Right-of-Use Asset 18.1M USD +23.4%
Other Assets, Noncurrent 0 USD -100%
Assets 757M USD +66.4%
Accounts Payable, Current 5.27M USD -19.4%
Employee-related Liabilities, Current 8.17M USD +53.7%
Accrued Liabilities, Current 20M USD +46.6%
Contract with Customer, Liability, Current 925K USD
Liabilities, Current 34.7M USD +63.4%
Operating Lease, Liability, Noncurrent 15.7M USD +22.3%
Liabilities 50.4M USD +47.9%
Retained Earnings (Accumulated Deficit) -451M USD +4%
Stockholders' Equity Attributable to Parent 707M USD +67.9%
Liabilities and Equity 757M USD +66.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 161M USD
Net Cash Provided by (Used in) Financing Activities 157M USD +45.6%
Net Cash Provided by (Used in) Investing Activities -565K USD +40.3%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 40.6M shares +12.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 161M USD +44.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 692M USD +69.9%
Deferred Tax Assets, Valuation Allowance 150M USD +51%
Deferred Tax Assets, Gross 155M USD +50.6%
Operating Lease, Liability 18.9M USD +30.6%
Depreciation 344K USD +24.2%
Payments to Acquire Property, Plant, and Equipment 565K USD -40.3%
Lessee, Operating Lease, Liability, to be Paid 25.8M USD +20.8%
Property, Plant and Equipment, Gross 7.19M USD +22.8%
Operating Lease, Liability, Current 2.23M USD +103%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4M USD +59.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.8M USD +56.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.94M USD +0.29%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.13M USD +60%
Deferred Tax Assets, Operating Loss Carryforwards 45.1M USD +24.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.25M USD +60%
Additional Paid in Capital 1.16B USD +30%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 5.17M USD +41%
Share-based Payment Arrangement, Expense 35.4M USD +7.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%